具有HLA遗传易感性儿童中1型糖尿病快速进展者的特征分析
在芬兰DIPP研究中监测7410名HLA易感儿童,中位随访16.2年,248名自身抗体血清转换者中42名(17%)为快速进展者(血清转换后1.5年内进展为1型糖尿病)。快速进展者血清转换时年龄更小、自身抗体滴度更高、多抗体阳性更常见,且在高危HLA基因型者中FUT2分泌型基因型更普遍,血清转换年龄呈双峰分布(<5岁和>7岁)。
要点
- 快速进展者血清转换后中位0.51年诊断1型糖尿病,慢进展者为5.4年,血清转换年龄呈双峰分布(<5岁和>7岁)。
- 快速进展者较慢进展者多抗体(≥2种)阳性频率更高,血清转换时ICA、IAA和IA-2A滴度更高。
- 高危HLA基因型携带者中,快速进展者FUT2分泌型基因型患病率更高。
核心结论
- 血清转换时,快速进展至1型糖尿病的个体特征为年龄更小、自身抗体滴度更高、多抗体阳性以及FUT2 SNP患病率更高。
- 快速进展者血清转换年龄的双峰特征首次表明快速进展不仅发生于幼儿,也发生于青春期早期儿童。
- 快速进展者可能受益于仔细的临床随访和早期预防措施。
研究设计与样本
- 研究纳入芬兰1型糖尿病预测与预防(DIPP)研究中7410名HLA易感儿童,从出生起监测β细胞自身免疫和1型糖尿病,中位随访16.2年(范围0.9-21.1年)。
- 检测胰岛细胞抗体(ICA)及胰岛素(IAA)、GAD(GADA)和胰岛抗原2(IA-2A)自身抗体作为β细胞自身免疫标志物。
- 快速进展定义为自身抗体血清转换后1.5年内进展为临床1型糖尿病。
- 分析快速进展与人口学、自身抗体特征及遗传标志物(包括25个非HLA SNPs)的关联。
主要发现
- 1550名儿童(21%)在至少两份样本中至少一种糖尿病相关自身抗体阳性,其中248名(16%)血清转换者在2015年底前进展为1型糖尿病。
- 快速进展者(n=42,17%)从血清转换至诊断的中位时间为0.51年,慢进展者为5.4年。
- 快速进展可见于年幼(<5岁)和青春期早期(>7岁)儿童,导致血清转换年龄呈双峰分布。
- 与慢进展者相比,快速进展者多抗体(≥2种)阳性频率更高,血清转换时ICA、IAA和IA-2A滴度更高,且在高危HLA基因型携带者中FUT2分泌型基因型患病率更高。
- 与自身抗体阳性非进展者相比,快速进展者更年轻,更可能携带高危HLA基因型和PTPN22基因易感SNP,ICA、IAA、GADA和IA-2A阳性及多阳性频率更高,血清转换时四种自身抗体滴度均更高。
临床怎么用
- 作者认为快速进展者可能受益于仔细的临床随访和早期预防措施。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: In this study, we aimed to characterise rapid progressors to type 1 diabetes among children recruited from the general population, on the basis of HLA-conferred disease susceptibility. METHODS: We monitored 7410 HLA-predisposed children participating in the Finnish Type 1 Diabetes Prediction and Prevention (DIPP) study for the development of beta cell autoimmunity and type 1 diabetes from birth over a median follow-up time of 16.2 years (range 0.9-21.1 years). Islet cell antibodies (ICA) and autoantibodies to insulin (IAA), GAD (GADA) and islet antigen 2 (IA-2A) were assessed as markers of beta cell autoimmunity. Rapid progression was defined as progression to clinical type 1 diabetes within 1.5 years of autoantibody seroconversion. We analysed the association between rapid progression and demographic and autoantibody characteristics as well as genetic markers, including 25 non-HLA SNPs predisposing to type 1 diabetes. RESULTS: Altogether, 1550 children (21%) tested positive for at least one diabetes-associated autoantibody in at least two samples, and 248 (16%) of seroconverters progressed to type 1 diabetes by the end of 2015. The median time from seroconversion to diagnosis was 0.51 years in rapid progressors (n = 42, 17%) and 5.4 years in slower progressors. Rapid progression was observed both among young (<5 years) and early pubertal children (>7 years), resulting in a double-peak distribution of seroconversion age. Compared with slower progressors, rapid progressors had a higher frequency of positivity for multiple (≥2) autoantibodies and had higher titres of ICA, IAA and IA-2A at seroconversion, and there was a higher prevalence of the secretor genotype in the FUT2 gene among those carrying the high-risk HLA genotype. Compared with autoantibody-positive non-progressors, rapid progressors were younger, were more likely to carry the high-risk HLA genotype and a predisposing SNP in the PTPN22 gene, had higher frequency of ICA, IAA, GADA and IA-2A positivity and multipositivity, and had higher titres of all four autoantibodies at seroconversion. CONCLUSIONS/INTERPRETATION: At seroconversion, individuals with rapid progression to type 1 diabetes were characterised by a younger age, higher autoantibody titres, positivity for multiple autoantibodies and higher prevalence of a FUT2 SNP. The double-peak profile for seroconversion age among the rapid progressors demonstrates for the first time that rapid progression may take place not only in young children but also in children in early puberty. Rapid progressors might benefit from careful clinical follow-up and early preventive measures.
引用
- Pöllänen PM, Lempainen J, Laine AP, et al. Characterisation of rapid progressors to type 1 diabetes among children with HLA-conferred disease susceptibility. Diabetologia. 2017. PMID: 28364254. doi:10.1007/s00125-017-4258-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。